Balance Sheet
Cash Flow Statement
Amortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash from Financing Activities: 2018-2024

Historic Cash from Financing Activities for Legend Biotech (LEGN) over the last 7 years, with Dec 2024 value amounting to $5.7 million.

  • Legend Biotech's Cash from Financing Activities fell 84.22% to $670,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $14,000, marking a year-over-year decrease of 99.80%. This contributed to the annual value of $5.7 million for FY2024, which is 99.28% down from last year.
  • Latest data reveals that Legend Biotech reported Cash from Financing Activities of $5.7 million as of FY2024, which was down 99.28% from $791.5 million recorded in FY2023.
  • In the past 5 years, Legend Biotech's Cash from Financing Activities ranged from a high of $791.5 million in FY2023 and a low of $5.7 million during FY2024.
  • Its 3-year average for Cash from Financing Activities is $391.7 million, with a median of $378.0 million in 2022.
  • Per our database at Business Quant, Legend Biotech's Cash from Financing Activities spiked by 4,119.82% in 2020 and then crashed by 99.28% in 2024.
  • Over the past 5 years, Legend Biotech's Cash from Financing Activities (Yearly) stood at $618.9 million in 2020, then grew by 1.26% to $626.7 million in 2021, then tumbled by 39.68% to $378.0 million in 2022, then skyrocketed by 109.40% to $791.5 million in 2023, then slumped by 99.28% to $5.7 million in 2024.